Axon Enterprise (NASDAQ:AXON – Free Report) had its price objective increased by Argus from $460.00 to $600.00 in a report issued on Thursday, Marketbeat Ratings reports. The firm currently has a buy rating on the biotechnology company’s stock.
AXON has been the subject of several other reports. Barclays boosted their price target on Axon Enterprise from $523.00 to $688.00 and gave the company an “overweight” rating in a research note on Thursday, August 6th. Weiss Ratings reissued a “hold (c-)” rating on shares of Axon Enterprise in a report on Wednesday, August 5th. Citizens Jmp reissued a “market outperform” rating and set a $700.00 target price on shares of Axon Enterprise in a report on Thursday, June 25th. JPMorgan Chase & Co. boosted their target price on shares of Axon Enterprise from $750.00 to $755.00 and gave the company an “overweight” rating in a research report on Thursday, May 7th. Finally, TD Cowen restated a “buy” rating on shares of Axon Enterprise in a research note on Wednesday, July 22nd. Fourteen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Axon Enterprise currently has an average rating of “Moderate Buy” and an average target price of $721.57.
View Our Latest Stock Analysis on AXON
Axon Enterprise Trading Down 4.2%
Axon Enterprise (NASDAQ:AXON – Get Free Report) last posted its earnings results on Tuesday, August 4th. The biotechnology company reported $1.88 EPS for the quarter, beating the consensus estimate of $1.84 by $0.04. The company had revenue of $904.39 million for the quarter, compared to the consensus estimate of $876.42 million. Axon Enterprise had a return on equity of 2.84% and a net margin of 6.19%.The firm’s revenue for the quarter was up 35.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.12 earnings per share. As a group, analysts predict that Axon Enterprise will post 2.04 earnings per share for the current year.
Insider Activity at Axon Enterprise
In other Axon Enterprise news, CEO Patrick W. Smith sold 9,930 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $548.77, for a total value of $5,449,286.10. Following the sale, the chief executive officer owned 3,031,067 shares in the company, valued at $1,663,358,637.59. This trade represents a 0.33% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Jeffrey C. Kunins sold 9,605 shares of the firm’s stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $626.70, for a total transaction of $6,019,453.50. Following the completion of the sale, the insider owned 97,761 shares in the company, valued at $61,266,818.70. This represents a 8.95% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 56,380 shares of company stock valued at $32,582,366. 4.20% of the stock is owned by insiders.
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of AXON. Creative Financial Designs Inc. ADV bought a new stake in Axon Enterprise during the 4th quarter worth $28,000. Keating Financial Advisory Services Inc. bought a new position in Axon Enterprise in the second quarter valued at about $31,000. AlphaCentric Advisors LLC bought a new position in Axon Enterprise in the fourth quarter valued at about $34,000. Darwin Wealth Management LLC acquired a new stake in shares of Axon Enterprise during the second quarter valued at about $37,000. Finally, Washington Trust Advisors Inc. boosted its stake in shares of Axon Enterprise by 1,300.0% during the second quarter. Washington Trust Advisors Inc. now owns 70 shares of the biotechnology company’s stock valued at $39,000 after purchasing an additional 65 shares in the last quarter. 79.08% of the stock is currently owned by institutional investors.
About Axon Enterprise
Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.
Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.
Featured Stories
- Five stocks we like better than Axon Enterprise
- Zscaler’s Strong Quarter Still Left Investors Waiting on 1 Key Signal
- Is Duolingo the Next Netflix-Style Comeback Story?
- GitLab’s AI Tools Are Starting to Turn Developer Demand Into Real Revenue
- GTA VI’s Console Problem Isn’t Take-Two’s Problem
Receive News & Ratings for Axon Enterprise Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axon Enterprise and related companies with MarketBeat.com's FREE daily email newsletter.
